Is it reasonable to administer antenatal corticosteroids to a 22‑week gestation patient with monochorionic‑diamniotic twins who underwent a rescue cerclage for a 4‑cm cervical dilation at 19 weeks?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, administering antenatal corticosteroids at 22 weeks is reasonable in this high-risk scenario

Given the extremely high risk of periviable delivery in this patient with monochorionic-diamniotic twins, 4 cm cervical dilation, and recent rescue cerclage, antenatal corticosteroids should be administered at 22 weeks if there is intent to pursue neonatal resuscitation. This recommendation aligns with evolving evidence and recent guideline updates supporting corticosteroid use at this gestational age when active neonatal intervention is planned.

Clinical Context and Risk Assessment

This patient represents an exceptionally high-risk scenario:

  • Monochorionic-diamniotic twins carry inherent increased preterm birth risk
  • 4 cm cervical dilation at 19 weeks indicates severe cervical insufficiency
  • Rescue cerclage placement suggests imminent delivery risk, though successful cases have been reported 1, 2
  • Current gestational age of 22 weeks places her at the threshold of viability

The critical question is not whether she might deliver prematurely, but rather when delivery will occur and whether the pregnancy can be prolonged even briefly.

Evidence Supporting Corticosteroid Administration at 22 Weeks

Guideline Evolution

The 2016 ACOG periviable birth guideline noted that at 22 weeks of gestation, antenatal corticosteroids showed no significant difference in death and neurodevelopmental impairment outcomes (90.2% vs 93.1%) 3. However, this guideline has been superseded by more recent evidence and practice changes.

Following accumulation of supportive data, ACOG and SMFM published a 2021 clinical practice advisory recommending consideration of antenatal corticosteroids at 22 weeks when neonatal resuscitation is planned 4. This advisory has demonstrably changed practice, with corticosteroid use at 22 weeks increasing from 13.5% in 2016 to 42.9% in 2022—a more than 3-fold increase 5.

Twin-Specific Evidence

Most importantly for this case, recent twin-specific data strongly supports corticosteroid use at 22 weeks. A 2026 nationwide study of 15,833 twin births at 22-26 weeks found that antenatal corticosteroids were associated with significantly higher neonatal survival at 22-23 weeks (55.9% vs 26.8%; adjusted OR 3.66,95% CI 2.95-4.55) 5. When limited to neonates receiving active postnatal intervention, the survival benefit remained significant at 22 weeks (adjusted OR 2.5,95% CI 1.77-3.54) 5.

Singleton Data Supporting the Approach

Additional observational studies in singletons demonstrate that among resuscitated neonates at 22 weeks, survival to 1 year was 45.2% with corticosteroid exposure versus 27.8% without (adjusted RR 1.6,95% CI 1.2-2.1) 6. The benefit was particularly pronounced in infants weighing 500-699 grams 6.

Decision-Making Algorithm

Step 1: Establish Goals of Care

  • Conduct multidisciplinary counseling involving obstetrics, neonatology, and the patient
  • Determine whether active neonatal resuscitation will be pursued if delivery occurs at 22-23 weeks
  • If resuscitation is NOT planned, corticosteroids should not be administered

Step 2: If Resuscitation is Planned

  • Administer betamethasone (12 mg IM every 24 hours × 2 doses) or dexamethasone (6 mg IM every 12 hours × 4 doses)
  • Optimal benefit occurs when delivery happens 24 hours to 7 days after the first dose
  • Given the high likelihood of imminent delivery with 4 cm dilation, timing is critical

Step 3: Concurrent Management

  • Continue expectant management with the cerclage in place
  • Monitor closely for signs of infection, membrane rupture, or labor
  • Consider magnesium sulfate for neuroprotection if delivery appears imminent (recommended before 30 weeks per guideline) 3
  • Antibiotics are indicated if membranes rupture but NOT for pregnancy prolongation with intact membranes and preterm labor 3

Critical Caveats

Twin-Specific Considerations

The 2024 SMFM guideline on short cervix management recommends against routine use of progesterone, pessary, or cerclage for cervical shortening in twin gestations outside clinical trials 7. However, this patient already has a rescue cerclage in place for advanced dilation—a different clinical scenario than prophylactic intervention for short cervix alone.

Limitations of Current Evidence

  • All supporting data for 22-week corticosteroids comes from observational studies, not randomized trials 8
  • Long-term neurodevelopmental outcomes at 22 weeks remain poorly characterized 8
  • The twin-specific data, while recent and robust, only addresses short-term neonatal outcomes 5

Concordance of Prenatal and Postnatal Plans

The decision to give corticosteroids MUST align with the neonatal resuscitation plan 8. Administering corticosteroids while planning comfort care only creates false expectations and is not evidence-based. This requires explicit, documented discussion with neonatology before proceeding.

Common Pitfalls to Avoid

  1. Administering corticosteroids without neonatology involvement: This creates discordant prenatal-postnatal management
  2. Delaying administration hoping to reach 23 weeks: With 4 cm dilation, delivery may occur at any moment; the window for benefit may close
  3. Assuming twin data mirrors singleton data: While recent twin-specific evidence is reassuring, twins have unique risks
  4. Forgetting to reassess goals of care: Clinical evolution (e.g., chorioamnionitis, abruption) may change the appropriateness of aggressive intervention

In summary, corticosteroid administration at 22 weeks in this twin gestation with advanced cervical dilation and rescue cerclage is reasonable and supported by recent evidence, provided there is a clear plan for neonatal resuscitation and multidisciplinary consensus on goals of care 5, 4, 6.

References

1
Research

Successful Rescue Cerclage in a Monochorionic Diamniotic Twin Pregnancy at 20 Weeks: Case Report and Overview of Literature.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2018

3
Guideline

periviable birth: interim update.

American Journal of Obstetrics and Gynecology, 2016

8
Research

Antenatal Corticosteroids at 21-23 Weeks of Gestation.

Obstetrics and gynecology, 2024

Related Questions

In a 45-year-old man with severe sepsis from multifocal pneumonia, who is intubated, hypotensive on vasopressors, anuric, volume overloaded, hyperkalemic, and acidotic with markedly elevated creatinine and BUN, what is the preferred renal replacement therapy?
How should a 50‑year‑old woman at term with a twin pregnancy (IVF) and a history of multiple surgeries for wandering fibroids and two port‑site hernioplasties be managed when she presents with pregnancy‑induced hypertension (PIH), moderate low‑protein ascites, a large well‑circumscribed infra‑hepatic mass, and elevated cancer antigen 125 (CA 125)?
What is the appropriate management plan for a 58-year-old female with a 17-year history of chronic cough after pneumonia, intermittent sputum production, dyspnea on exertion, nicotine dependence with a 48 pack‑year smoking history (currently smoking ~1 pack every two weeks), who is not on inhalers and requires smoking cessation therapy, a short‑acting bronchodilator inhaler, a 14‑day course of nebulized ipratropium bromide, a cough suppressant, a chest radiograph, and glucose monitoring before a corticosteroid injection?
In an adult with an acute cough from a viral or uncomplicated bacterial respiratory infection, what is the recommended treatment and how do dexamethasone and prednisone compare for short‑course corticosteroid therapy?
In a 24-year-old man with recurrent proximal lower‑limb weakness causing difficulty gripping slippers and rising from a squat, prior episodes fully responsive to steroids but a current steroid‑resistant relapse, and no cranial nerve, sensory, or cerebellar involvement, what is the appropriate diagnostic work‑up and acute management?
What are some case studies of patients with anti‑Yo (anti‑PCA‑1) antibody positivity?
What are the differences between metabolic dysfunction‑associated steatohepatitis (MASH) and non‑alcoholic steatohepatitis (NASH) regarding definition, diagnosis, and management?
Are inhalers such as Incruse (umeclidinium bromide) contraindicated in hypertrophic obstructive cardiomyopathy?
In a quadriplegic patient with hypotension (blood pressure ~90/50 mm Hg), what are the appropriate management options for an enlarged prostate (benign prostatic hyperplasia)?
Can diabetic ketoacidosis still be present if ketones are normal, despite a bicarbonate of 14 mmol/L and a glucose of 21 mmol/L (≈380 mg/dL)?
A patient taking guanfacine 1 mg at bedtime continues to experience hyperarousal and tantrums; how should the guanfacine dose be adjusted?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.